Jane Street
NGNE icon

Jane Street’s Neurogene NGNE Stock Holding History

Jane Street’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-15,105
Closed -$293K – 12520
2025
Q4 		$311K Sell
15,105
-47,302
-76% -$1.18M ﹤0.01% 8760
2025
Q3 		$1.08M Buy
+62,407
New +$1.25M ﹤0.01% 6154
2024
Q4 		– Sell
-7,717
Closed -$287K – 10177
2024
Q3 		$324K Buy
+7,717
New +$299K ﹤0.01% 7909
2024
Q2 		– Sell
-54,888
Closed -$2.79M – 9923
2024
Q1 		$2.79M Buy
+54,888
New +$1.83M ﹤0.01% 3517
2023
Q1 		– Sell
-3,033
Closed -$30.9K – 9621
2022
Q4 		$30.9K Buy
+3,033
New +$31.3K ﹤0.01% 8499
2020
Q3 		– Sell
-2,149
Closed -$714K – 7661
2020
Q2 		$714K Buy
2,149
+133
+7% +$34.7K ﹤0.01% 4554
2020
Q1 		$459K Buy
+2,016
New +$415K ﹤0.01% 3710
2016
Q4 		– Sell
-784
Closed -$209K – 4424
2016
Q3 		$209K Buy
+784
New +$158K ﹤0.01% 3677
2014
Q4 		– Sell
-1,000
Closed -$133K – 2846
2014
Q3 		$133K Buy
+1,000
New +$152K ﹤0.01% 2315
2014
Q2 		– Sell
-624
Closed -$159K – 2935
2014
Q1 		$159K Buy
+624
New +$160K ﹤0.01% 2430

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Jane Street's NGNE Position: Q1 2026 in Review

Jane Street sold out of Neurogene (NGNE) in Q1 2026, closing a stake of 15,105 shares — an estimated $293K sold.

Jane Street first reported a position in NGNE in Q1 2014 and held it in 10 quarters. The position peaked at $2.79M in Q1 2024. 96 funds tracked by Wall St. Rank hold NGNE as of Q1 2026.

  • Jane Street reported no remaining Neurogene position as of Q1 2026 after selling out during the quarter.
  • Jane Street sold 15,105 Neurogene shares in Q1 2026, an estimated $293K.
  • Jane Street first reported a position in Neurogene in Q1 2014 and held it in 10 quarters.
  • Jane Street's Neurogene position peaked at $2.79M in Q1 2024.
  • 96 funds tracked by Wall St. Rank held Neurogene as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.